Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …

The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity
within the tumour microenvironment. Consequently, multiple clinical strategies are being …

Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …

Adenosine is a ubiquitous endogenous autacoid whose effects are triggered through the
enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Due to the rapid …

Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Breast cancer progression is a complex process controlled by genetic and epigenetic factors
that coordinate the crosstalk between tumor cells and the components of tumor …

Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1
(PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a …

T cells play a critical role in cancer control, but a range of potent immunosuppressive
mechanisms can be upregulated in the tumor microenvironment (TME) to abrogate their …

While intracellular adenosine triphosphate (ATP) occupies a key position in the bioenergetic
metabolism of all the cellular compartments that form the tumor microenvironment (TME) …